MicroRNA-191 promotes pancreatic cancer progression by targeting USP10

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12157-12163

  Liu, Hua ^a   Xu, Xuan Fu ^a   Zhao, Yan ^a   Tang, Mao Chun ^a   Zhou, Ying Qun ^a   Lu, Jie ^b   Gao, Feng Hou ^b  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gene regulation; MicroRNA; miR 191; P53; Pancreatic cancer; UPS10

Indexed keywords

DEUBIQUITINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA; MICRORNA 191; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN SPECIFIC PEPTIDASE 10; UNCLASSIFIED DRUG; MIRN191 MICRORNA, HUMAN; UBIQUITIN THIOLESTERASE; USP10 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G0 PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; MICRORNAS; NF-KAPPA B; PANCREATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN THIOLESTERASE;

EID: 84925284791     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2521-9     Document Type: Article

References (24)

1. Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970–2009. J Natl Cancer Inst. 2013;105:1694–700.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;33:281–97.
3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;33:215–33.
4. Sun T, Kong X, Du Y, Li Z. Aberrant microRNAs in pancreatic cancer: researches and clinical implications. Gastroenterol Res Pract. 2014;2014:386561.
5. Neureiter D, Jäger T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol. 2014;20:7830–48.
6. Naderi E, Mostafaei M, Pourshams A, Mohamadkhani A. Network of microRNAs-mRNAs interactions in pancreatic cancer. Biomed Res Int. 2014;2014:534821.
7. Qin S, Zhu Y, Ai F, Li Y, Bai B, Yao W, et al. MicroRNA-191 correlates with poor prognosis of colorectal carcinoma and plays multiple roles by targeting tissue inhibitor of metalloprotease 3. Neoplasma. 2014;61:27–34.
8. Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010;70:8077–87.
9. Colamaio M, Borbone E, Russo L, Bianco M, Federico A, Califano D, et al. miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab. 2011;96:E1915–24.
10. Kent OA, Mullendore M, Wentzel EA, López-Romero P, Tan AC, Alvarez H, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009;8:2013–24.
11. Ryu JK, Matthaei H, Dal Molin M, Hong SM, Canto MI, Schulick RD, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011;11:343–50.
12. Di Leva G, Piovan C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet. 2013;9:e1003311.
13. Soncini C, Berdo I, Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene. 2001;20:3869–79.
14. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140:384–96.
15. Niu J, Shi Y, Xue J, Miao R, Huang S, Wang T, et al. USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO. EMBO J. 2013;32:3206–19.
16. He Y, Cui Y, Wang W, Gu J, Guo S, Ma K, et al. Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-miR-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia. 2011;13:841–53.
17. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223–34.
18. Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q, et al. USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 2013;5:1639–49.
19. Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS, Yang GF, et al. Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumour Biol. 2014;35:3845–53.
20. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol. 2001;13:332–7.
21. Cairo S, Armengol C, Buendia MA. Activation of Wnt and Myc signaling in hepatoblastoma. Front Biosci (Elite Ed). 2012;4:480–6.
22. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15:283–93.
23. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, Travali S, et al. The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol. 2012;40:1733–47.
24. Ling S, Feng T, Jia K, Tian Y, Li Y. Inflammation to cancer: the molecular biology in the pancreas (review). Oncol Lett. 2014;7:1747–54.